Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tibolone
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland
Details : Developed by Mithra as the bioequivalent version of Livial® Tibelia® is a complex oral formulation composed of tibolone. Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia® in Liechtenstein...
Brand Name : Tibelia
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 11, 2020
Lead Product(s) : Tibolone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
